# Integrative multi-omics analysis reveals the interaction mechanisms between gut microbiota metabolites and ferroptosis in rheumatoid arthritis

**Authors:** Lifang Liang, Huaguo Liang, Min He, Huiling Zhang, Peifeng Ke

PMC · DOI: 10.3389/fimmu.2025.1608262 · 2025-07-09

## TL;DR

This study explores how gut microbiota metabolites interact with ferroptosis in rheumatoid arthritis, identifying GPX3 and MYC as key regulators and potential therapeutic targets.

## Contribution

The study introduces GPX3 and MYC as novel ferroptosis regulators in RA and suggests gut metabolites like Diosgenin may modulate these genes.

## Key findings

- GPX3 and MYC were identified as critical ferroptosis regulators in rheumatoid arthritis through multi-omics and machine learning analyses.
- Molecular docking and dynamics simulations showed Diosgenin binds stably to GPX3, suggesting a potential therapeutic role in RA.
- High GPX3 and MYC expression correlates with interferon response and TNFA signaling, while low expression relates to fatty acid metabolism.

## Abstract

Rheumatoid arthritis (RA) is an autoimmune disease characterized by chronic synovitis and joint destruction. To systematically investigate the regulatory relationship between key ferroptosis genes and gut metabolites in RA, this study employed an integrative multi-omics approach combined with machine learning algorithms and single-cell transcriptomic data, identifying and validating GPX3 and MYC as potential critical ferroptosis regulators in RA.

First, 16 candidate genes were obtained by intersecting WGCNA, differential expression analysis results, and targets related to ferroptosis and gut microbiota. Following cross-validation with machine learning approaches including LASSO, SVM, and RFE-RF, GPX3 and MYC were ultimately identified as crucial genes. GSVA and GSEA analyses revealed that high expression of GPX3 and MYC was enriched in interferon response and TNFA signaling pathways, while their low expression was associated with fatty acid metabolism and oxidative phosphorylation pathways. Further single-cell RNA sequencing analysis demonstrated that MYC was expressed in multiple immune cell types, particularly in CD4+ T cells and NK cells. Ferroptosis scoring for CD8+ T cells and subsequent cell communication analysis revealed stronger interactions between CD8+ T cells with higher ferroptosis scores and other immune cells through IFN-II and CCL signaling, further intensifying the activation of the inflammatory microenvironment. Additionally, molecular docking analysis of GPX3 and MYC with the gut metabolites Diosgenin and Differentiation-inducing factor 3 (DIF-3) respectively showed that the GPX3-Diosgenin complex had the lowest binding energy, and a 100 ns molecular dynamics simulation was performed on this complex. Results showed good stability of the complex across indicators such as RMSD, RMSF, SASA, and radius of gyration, suggesting that Diosgenin may intervene in ferroptosis and inflammatory injury in RA by binding to and modulating GPX3 function.

This study elucidated the multifaceted mechanisms of GPX3 and MYC in RA pathogenesis and preliminarily validated the potential role of gut metabolites in mediating ferroptosis regulation, offering novel theoretical foundations and potential strategies for diagnostic biomarker screening and targeted therapy in RA.

## Linked entities

- **Genes:** GPX3 (glutathione peroxidase 3) [NCBI Gene 2878], MYC (MYC proto-oncogene, bHLH transcription factor) [NCBI Gene 4609]
- **Chemicals:** Diosgenin (PubChem CID 99474)
- **Diseases:** rheumatoid arthritis (MONDO:0008383)

## Full-text entities

- **Genes:** CD8A (CD8 subunit alpha) [NCBI Gene 925] {aka CD8, CD8alpha, IMD116, Leu2, p32}, GPX3 (glutathione peroxidase 3) [NCBI Gene 2878] {aka GPx-P, GSHPx-3, GSHPx-P}, GGNBP2 (gametogenetin binding protein 2) [NCBI Gene 79893] {aka DIF-3, DIF3, LCRG1, LZK1, ZFP403, ZNF403}, TNF (tumor necrosis factor) [NCBI Gene 7124] {aka DIF, IMD127, TNF-alpha, TNFA, TNFSF2, TNLG1F}, CRYGEP (crystallin gamma E, pseudogene) [NCBI Gene 200575] {aka CCL, CRYG5, CRYGEP1, D2S1472, G2}, MYC (MYC proto-oncogene, bHLH transcription factor) [NCBI Gene 4609] {aka MRTL, MYCC, bHLHe39, c-Myc}, CD4 (CD4 molecule) [NCBI Gene 920] {aka CD4mut, IMD79, Leu-3, OKT4D, T4}
- **Diseases:** RA (MESH:D001172), inflammatory (MESH:D007249), autoimmune disease (MESH:D001327), joint destruction (MESH:D008105), synovitis (MESH:D013585)
- **Chemicals:** fatty acid (MESH:D005227), Diosgenin (MESH:D004144)

## Figures

9 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12283288/full.md

---
Source: https://tomesphere.com/paper/PMC12283288